125 related articles for article (PubMed ID: 2953009)
1. [Biological criteria of isolated Graves' ophthalmopathy].
Laferrère B; Madec AM; Orgiazzi J; Mornex R
Presse Med; 1987 Apr; 16(15):711-4. PubMed ID: 2953009
[TBL] [Abstract][Full Text] [Related]
2. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease.
Wiersinga WM; Smit T; van der Gaag R; Koornneef L
J Endocrinol Invest; 1988 Sep; 11(8):615-9. PubMed ID: 2907524
[TBL] [Abstract][Full Text] [Related]
3. Chronology of Graves' ophthalmopathy in an incidence cohort.
Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736
[TBL] [Abstract][Full Text] [Related]
4. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
5. The differential diagnostic problems in unilateral euthyroid Graves' ophthalmopathy.
Perrild H; Feldt-Rasmussen U; Bech K; Ahlgren P; Hansen JM
Acta Endocrinol (Copenh); 1984 Aug; 106(4):471-6. PubMed ID: 6548073
[TBL] [Abstract][Full Text] [Related]
6. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
[TBL] [Abstract][Full Text] [Related]
7. The TRH test: its value in the diagnosis of Graves' ophthalmopathy.
Jackson WB; Tolis G; Chertman M
Can J Ophthalmol; 1978 Jan; 13(1):10-4. PubMed ID: 416892
[TBL] [Abstract][Full Text] [Related]
8. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
10. Studies on the occurrence of ophthalmopathy in Graves' disease.
Marcocci C; Bartalena L; Bogazzi F; Panicucci M; Pinchera A
Acta Endocrinol (Copenh); 1989 Apr; 120(4):473-8. PubMed ID: 2718699
[TBL] [Abstract][Full Text] [Related]
11. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
12. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
13. A study of thyroid function after subtotal thyroidectomy for Graves' disease: particularly on TRH tests, T3 suppression tests and antithyroid antibodies in euthyroid patients.
Fukino O; Tamai H; Fujii S; Ohsako N; Matsubayashi S; Kuma K; Nagataki S
Acta Endocrinol (Copenh); 1983 May; 103(1):28-33. PubMed ID: 6407253
[TBL] [Abstract][Full Text] [Related]
14. Thyroid-stimulating antibodies in patients with autoimmune disorders.
Strakosch CR; Joyner D; Wall JR
J Clin Endocrinol Metab; 1978 Aug; 47(2):361-5. PubMed ID: 263731
[TBL] [Abstract][Full Text] [Related]
15. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
[TBL] [Abstract][Full Text] [Related]
16. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.
Khoo DH; Ho SC; Seah LL; Fong KS; Tai ES; Chee SP; Eng PH; Aw SE; Fok AC
Thyroid; 1999 Dec; 9(12):1175-80. PubMed ID: 10646655
[TBL] [Abstract][Full Text] [Related]
17. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
[TBL] [Abstract][Full Text] [Related]
18. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
19. Graves' ophthalmopathy. A clinical and immunologic review.
Sergott RC; Glaser JS
Surv Ophthalmol; 1981; 26(1):1-21. PubMed ID: 6895125
[TBL] [Abstract][Full Text] [Related]
20. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
